Enliven to sell $200M in stock after positive drug trial
Enliven Therapeutics recently reported positive data from a clinical trial for one of its drug candidates, and plans to raise $200 million in a public stock offering.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Enliven Therapeutics Inc. (Nasdaq: ELVN), a clinical-stage precision oncology company that reported its first quarter…
-
Edgewise Therapeutics plans to sell nearly 10 million shares of its common stock at $20.13,…
-
Gogo Inc., a Broomfield-based provider of broadband connectivity services for the business-aviation market, saw its…
-
Crocs Inc.’s stock price spiked on Thursday morning after the casual shoe brand topped Wall…
